Financial Crunch Time For Inspiration As Hemophilia Pact With Ipsen Gets Surprise Revamp
Executive Summary
Inspiration Biopharma and hemophilia partner Ipsen have renegotiated their nearly three-year-old deal around two late-stage clinical assets. As part of the new deal, Ipsen has given up its option to buy Inspiration, providing the biotech with the opportunity – and the necessity – to find fresh financing from new backers in the coming months.
You may also be interested in...
Baxter’s Factor IX Product For Hemophilia B Advances To FDA
Baxter’s treatment could soon compete with Pfizer’s BeneFIX, the only commercially available recombinant factor IX protein for hemophilia B in the U.S. At least two other recombinant factor IX products are in Phase III trials.
Deals Of The Week: Allergan/Molecular Partners, Silence Therapeutics/MiReven, Pfizer/Mylan
The widely dispersed array of developmental therapies for conditions such as non-small cell lung cancer and type 2 diabetes begs the question of whether it would make more sense to have a biopharmaceutical industry based on solution-focused companies approaching a single problem from multiple angles.
In Seeking Focus, Ipsen Turns To Specialty Pharma Model
Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.